I looked it up. Lab analysis is listed as
Other Outcome Measures:
1. Change in size of lesion area by chest radiograph or CT [ Time Frame: Day 14 ]
2.Change from baseline in serum cytokine and chemokine levels [ Time Frame: Days 3, 7, and 14 ]
3.Change from baseline in CCR5 receptor occupancy levels for Tregs and macrophages [ Time Frame: Days 3, 7, and 14 ]
4.Change from baseline in CD3+, CD4+ and CD8+ T cell count [ Time Frame: Days 3, 7, and 14 ]
Those are Patterson's areas of expertise.
Primary Outcome Measures :
Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough) [ Time Frame: Day 14 ]
Note: The total score per patient ranges from 0 to 12 points. Each symptom is graded from 0 to 3. [0=none, 1=mild, 2=moderate, and 3=severe]. Higher scores mean a worse outcome. https://clinicaltrials.gov/ct2/show/NCT04343651?term=leronlimab&draw=2&rank=2
Nader likes to say, "If we meet our primary endpoint, we will shock the world!!" or words to that effect.